Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 2
2019 1
2020 4
2021 9
2022 10
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Logunov DY, et al. Among authors: dolzhikova iv. Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Lancet. 2021. PMID: 33545094 Free PMC article. Clinical Trial.
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Logunov DY, et al. Among authors: dolzhikova iv. Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4. Lancet. 2020. PMID: 32896291 Free PMC article. Clinical Trial.
COVID-19 vaccination and HIV-1 acquisition.
Logunov DY, Livermore DM, Ornelles DA, Bayer W, Marques E, Czerkinsky C, Dolzhikova IV, Ertl HC. Logunov DY, et al. Among authors: dolzhikova iv. Lancet. 2022 Apr 9;399(10333):e34-e35. doi: 10.1016/S0140-6736(22)00332-4. Lancet. 2022. PMID: 35397866 Free PMC article. No abstract available.
Virus-Vectored Ebola Vaccines.
Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, Tukhvatulin AI, Shcheblyakov DV, Voronina OL, Syromyatnikova SI, Borisevich SV, Pantyukhov VB, Babira VF, Kolobukhina LV, Naroditsky BS, Logunov DY, Gintsburg AL. Dolzhikova IV, et al. Acta Naturae. 2017 Jul-Sep;9(3):4-11. Acta Naturae. 2017. PMID: 29104771 Free PMC article.
[Review of candidate vaccines for the prevention of Lassa fever].
Popova OD, Zubkova OV, Ozharovskaia TA, Zrelkin DI, Voronina DV, Dolzhikova IV, Shcheblyakov DV, Naroditsky BS, Logunov DY, Gintsburg AL. Popova OD, et al. Among authors: dolzhikova iv. Vopr Virusol. 2021 May 15;66(2):91-102. doi: 10.36233/0507-4088-33. Vopr Virusol. 2021. PMID: 33993679 Review. Russian.
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
Favorskaya IA, Shcheblyakov DV, Esmagambetov IB, Dolzhikova IV, Alekseeva IA, Korobkova AI, Voronina DV, Ryabova EI, Derkaev AA, Kovyrshina AV, Iliukhina AA, Botikov AG, Voronina OL, Egorova DA, Zubkova OV, Ryzhova NN, Aksenova EI, Kunda MS, Logunov DY, Naroditsky BS, Gintsburg AL. Favorskaya IA, et al. Among authors: dolzhikova iv. Front Immunol. 2022 Feb 24;13:822159. doi: 10.3389/fimmu.2022.822159. eCollection 2022. Front Immunol. 2022. PMID: 35281053 Free PMC article.
SERS-Based Aptasensor for Rapid Quantitative Detection of SARS-CoV-2.
Zavyalova E, Ambartsumyan O, Zhdanov G, Gribanyov D, Gushchin V, Tkachuk A, Rudakova E, Nikiforova M, Kuznetsova N, Popova L, Verdiev B, Alatyrev A, Burtseva E, Ignatieva A, Iliukhina A, Dolzhikova I, Arutyunyan A, Gambaryan A, Kukushkin V. Zavyalova E, et al. Among authors: dolzhikova i. Nanomaterials (Basel). 2021 May 25;11(6):1394. doi: 10.3390/nano11061394. Nanomaterials (Basel). 2021. PMID: 34070421 Free PMC article.
SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case.
Mukhina OA, Fomina DS, Parshin VV, Gushchin VA, Dolzhikova IV, Shchetinin AM, Chudakov DM, Alekseeva E, Korostin D, Bazykin GA, Klink G, Logunov DY, Lysenko MA. Mukhina OA, et al. Among authors: dolzhikova iv. Hum Vaccin Immunother. 2022 Nov 30;18(6):2101334. doi: 10.1080/21645515.2022.2101334. Epub 2022 Aug 1. Hum Vaccin Immunother. 2022. PMID: 35914217 Free PMC article.
Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma.
Razumikhin M, Smolyanova T, Nikolaeva A, Orlova E, Ivanov A, Belyakova O, Vyaznikova T, Selezneva N, Perevozchikov A, Sokolova A, Zubkova N, Efimova I, Dolzhikova I, Logunov D, Sakanjan E. Razumikhin M, et al. Among authors: dolzhikova i. Immunotherapy. 2022 Oct;14(14):1133-1147. doi: 10.2217/imt-2022-0015. Epub 2022 Jul 27. Immunotherapy. 2022. PMID: 35892311 Free PMC article.
29 results